15 maj: Pandora regnskab kostede aktionærerne mere end 11 mia. kr.
15 maj: NNIT: Overrasket over fald i Novo-indtægter, men stærk vækst elle..
15-05-2018 17:23:06

NNIT A/S: 07/2018 Financial report for Q1 2018

Relateret indhold
12 okt - 
KORR: NNIT/Carnegie: Kursmålet hæves med 15 kr.
12 okt - 
NNIT/Canergie: Kursmålet hæves med 15 kr.
10 okt - 
NNIT/Danske: Hæver kursmål efter amerikansk opkøb
Relateret debat
17 sep - 
Vi kan vist takke Aktieinfo for dagens p..

Financial report for Q1 2018

NNIT delivers an operating profit margin of 8.7% while revenue declines by 2.3% despite a revenue increase of 12% from non-Novo Nordisk customers

Performance highlights for Q1 2018

  • Revenue from non-Novo Nordisk customers increased by 12% supported by strong growth from both enterprise and international life sciences customers of more than 20%. However, due to decline in revenue from the Novo Nordisk Group of 20% and the timing of Easter total revenue declined by 2.3% in reported currencies

  • Adjusted for the timing of Easter revenue development was almost flat  

  • The share of revenue from non-Novo Nordisk customers increased from 55 % in Q1 2017 to 63% in Q1 2018

  • Operating profit margin was 8.7% in reported currencies compared to 10.5% in 2017 

  • Adjusting for the timing of Easter the operating profit margin was 10.5%

  •  Net profit of DKK 46m in Q1 2018 was a decrease of 18% compared to Q1 2017. Adjusted for the timing of Easter net profit increased by 1.4% compared to last year

  •  Free cash flow for Q1 2018 was DKK 143m compared to DKK 163m in Q1 2017

  •  Order backlog for 2018 at the beginning of Q2 2018 was DKK 2,487m, an increase of 2.8% compared to the same time last year. The backlog for the following two years increased by 20%

  • Outlook for 2018 is:

  • Revenue growth of 3-6% in constant currencies (previously 4-7%)

  • Expected operating profit margin of 10-10.5% in constant currencies

  • The expected level of investments in 2018 is 6-8% of total revenue

    • Based on the strong cash flow NNIT will pay out an interim dividend in August 2018 of DKK 49.1m in cash equal to DKK 2 per share of a nominal value of DKK 10

    Per Kogut, CEO at NNIT says about the results for the first three months of 2018: "I am encouraged by the continued strong growth in particular the enterprise and international life sciences customer groups. The decline in revenue from the Novo Nordisk Group was larger than expected and we have therefore adjusted our revenue growth guidance for 2018 to 3-6%. Under these circumstances, I am pleased that we have maintained our operating profit margin guidance of 10-10.5%."

    Conference call details

    NNIT will host a teleconference May 16, 2018 at 10:30 CET about the financial report for Q1 2018. Please visit the NNIT webpage at www.nnit.com to access the teleconference, which can be found under 'Investors - Events & presentations'. Presentation material will be available on the website approximately one hour prior to the start of the presentation.

    Conference call details

    https://nnit.eventcdn.net/20180516

    Participant telephone numbers:

    Denmark:                     +45 3544 5583

    United Kingdom:           +44 20 3194 0544

    Sweden:                       +46 8 5664 2661

    United States:               +1 855 269 2604

      

    Financial Calendar 2018

    August 17, 2018       Interim report for the first six months of 2018

     

    August 22, 2018       Interim dividend ex dividend date

     

    August 23, 2018       Interim dividend record date

     

    August 24, 2018       Interim dividend payment date

     

    October 25, 2018      Interim report for the first nine months of 2018

    Contacts for further information

    Investor relations:

    Klaus Hosbond Skovrup

    Head of Investor Relations

    Tel: +45 3079 5355

    ksko@nnit.com

    Media relations:

    Helga Heyn

    NNIT Communications

    Tel: +45 3077 8141

    hhey@nnit.com

    Company announcement Q1 2018 EN


    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

    Source: NNIT A/S via Globenewswire

    Opret kommentar

    Relateret debat

    • 1 uge
    • 1 måned
    • 1 År
    Ingen indlæg

    Genmab-partners Darzalex-salg skuffer - aktien falder - NY

    16-10-2018 13:18:29
    Den amerikanske medicinalvirksomhed Johnson & Johnson, der er partner med danske Genmab, leverede i tredje kvartal en lidt bedre end ventet omsætning for hele forretningen, mens Darzalex-salget var skuffende. Samlet kom omsætningen ind på 20,35 mia. dollar mod analytikernes forventning på 20,05 mia. dollar ifølge Bloomberg News. Ud af det samlede salg stod Darzalex for 498 mio. dollar i kvartalet,..

    DSV/HSBC: Ingen sikkerhed for nyt Ceva-bud lige her og nu

    16-10-2018 11:42:02
    Efter at DSV for nylig bekræftede at have fået afvist et overtagelsestilbud af schweiziske Ceva Logistics, er der ingen sikkerhed for, at den danske transport- og logistikvirksomhed vil komme med et nyt og forhøjet bud inden for den nærmeste fremtid. Det vurderer Edward Stanford, analytiker i den britiske storbank HSBC, i forlængelse af sidste uges historie om, at bestyrelsen i Ceva Logistics ikke..

    Aktier/tendens: Chr. Hansen og kursmål i fokus i grønt marked

    16-10-2018 08:24:54
    Der er udsigt til et lysegrønt dansk aktiemarked tirsdag, hvis man spejder mod de amerikanske futures, som ligger i grønt med stigninger mellem 0,3 pct. og 0,5 pct. Det danske C25-indeks lukkede ellers surt mandag med et fald på 0,3 pct., og indekset fortsatte dermed sit negative spor, hvilket dog ser ud til at vende i dag.De asiatiske aktiemarkeder er i overvejende grønt undtagen i Kina, og den t..

    Mest læste nyheder

    • 24 timer
    • 48 timer
    • 1 uge
    1
    Genmab-partners Darzalex-salg skuffer - aktien falder - NY
    2
    Aktier/middag: Genmab og Ambu topper et velkørende C25
    3
    Genmab/Sydbank: Skuffende Darzalex-salg - prisjustering trækker ned
    4
    Erhvervskvinde trækker sig fra DR-program efter kritik - NY
    5
    Dansk eliteindeks lukker med sin højeste endagsstigning - NY

    Relaterede aktiekurser

    Nnit A/S 197,00 0,9% Stigning i aktiekurs
    Nnit Ord Shs 197,00 0,9% Stigning i aktiekurs

    Køb- og salgsanbefalinger

    • Trend
    • Pengemaskinen

    Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
    Aktieinformation leveres af Morningstar.
    Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
     
    17. oktober 2018 01:18:50
    (UTC+01:00) Brussels, Copenhagen, Madrid, Paris
    Version: LiveBranchBuild_20181005.3 - EUROWEB1 - 2018-10-17 01:18:50 - 2018-10-17 01:18:50 - 1 - Website: OKAY